Connect
← Return to Pancreatic Cancer Group: Introduce yourself and connect with others
Discussion
Pancreatic Cancer Group: Introduce yourself and connect with others
Pancreatic Cancer | Last Active: 10 hours ago | Replies (1371)Comment receiving replies
I spoke with my oncologist today after receiving the news that my cancer had spread to my liver despite my 12 rounds of Folfirinox. Turns out it has also spread to the soft tissue in my belly. So surgery is not an option. They are starting me on gemcitabene nab-Paclitaxel in 2 weeks. I understand the side effects of this cocktail will be worse than the Folfirinox. And my chances of good response are getting slimmer. My oncologist mentioned a new class of drugs that will be coming out at the end of the year that target the KRAS mutation, and I may be a candidate for that. Anyone have experience/knowledge of this new treatment?
Replies to "I spoke with my oncologist today after receiving the news that my cancer had spread to..."
Connect
There are a number of targeted treatments in clinical trials for KRAS mutations. The most common KRAS mutations for pancreatic cancer are G12D, G12V and G12R in that order. G12C was the first that became targetable a few years ago and occurs in only 1-3% of pancreatic cancer patients with a KRAS mutation.
The trial your oncologist is likely referring to is Revolution Medicine RMC-6236. It is expanding into phase III and is a pan-KRAS targeted therapy having effect on multiple KRAS variants. Another trial is RMC-9805 and there is one combining the RMC-6236 drug and the 9805 drug. Muratti Pharma has a G12D targeted therapy called MRTX-1133.
There are a number of KRAS trials coming on line. Check with PanCan.org and TriCanHealth.com that specialize in clinical trial searches for pancreatic cancer trials.